NCT05144035View on ClinicalTrials.gov

A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants

PHASE4RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Small for Gestational Age InfantGrowth Hormone TreatmentCognitive Developmental Disorder
Interventions
DRUG

PEG-rhGH

the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.

Trial Locations (1)

430000

RECRUITING

Wuhan Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER